Archive · 20 Aug 2026
Moderna shares surge as melanoma vaccine data sparks rally
Moderna makes vaccines and other medicines using a technology called mRNA.
Its stock price jumped sharply after it announced encouraging results for a melanoma treatment.
The treatment combines Moderna’s personalized vaccine with Merck’s KEYTRUDA medicine.
In a study, the combination helped high-risk melanoma patients stay free of cancer returning or spreading.
This was the first successful Phase 3 result for an individualized mRNA cancer treatment, according to the companies.
Merck’s stock also rose after the announcement.
Moderna’s business results were less dramatic, with only slightly higher revenue and a large loss in the latest quarter.
Investors were especially excited about the possible future of the cancer treatment, but the companies still need to share the data with regulators.
Moderna shares rose $111, or 177%, to close at $174.38 on Wednesday.
The company’s market capitalization increased from about $25 billion to $69 billion in one trading day.
The rally followed positive Phase 3 results for Moderna and Merck’s individualized mRNA melanoma treatment.
The trial met its primary recurrence-free survival endpoint and a key distant metastasis-free survival endpoint.
Moderna reported $145 million in second-quarter 2026 revenue and a $782 million net loss.
- Who
- Moderna and Merck, whose personalized mRNA melanoma treatment produced positive Phase 3 results; Moderna shareholders and investors responded to the announcement.
- What
- Moderna shares rose 177% after the companies reported that their experimental treatment reduced the risk of melanoma recurrence or death compared with KEYTRUDA alone.
- When
- Wednesday, August 19; the article also reports Moderna’s second-quarter 2026 financial results.
- Where
- The clinical study involved patients with resected stage IIB-IV melanoma; the article does not identify a single study location.
- Why
- Investors reacted to the treatment’s positive Phase 3 results and its potential as a new cancer therapy.
Bullish Market View
Cautious Financial View
Melanoma treatment prospects
Bullish Market View
The Phase 3 results are described as a landmark moment and the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.
Cautious Financial View
The data still must be presented at an international medical meeting and shared with regulatory authorities before the treatment can progress through the regulatory process.
Stock valuation
Bullish Market View
Investors pushed Moderna’s market capitalization up by about $44 billion in one trading day, reflecting enthusiasm about the treatment’s potential.
Cautious Financial View
The stock’s dramatic rise occurred despite Moderna’s continuing losses, declining cash balance, and weaker COVID sales in the United States and South America.
Business outlook
Bullish Market View
Moderna trimmed its 2026 operating-expense outlook by about $200 million and maintained a target of up to 10% revenue growth.
Cautious Financial View
The company reported only marginal revenue growth in the second quarter and expects to use cash for operations, research and development, and a $950 million litigation-settlement payment.
- Share-price move
- Moderna shares gained $111, or 177%, closing at $174.38.
- Market-capitalization increase
- Moderna’s valuation rose from approximately $25 billion to $69 billion in one day.
- Clinical endpoints
- The study met its primary recurrence-free survival endpoint and a key distant metastasis-free survival endpoint.
- Treatment comparison
- The combination showed a clinically meaningful improvement over KEYTRUDA alone in the adjuvant setting, according to the article.
- Second-quarter revenue
- Moderna reported $145 million in Q2 2026 revenue, compared with $142 million a year earlier.
- Second-quarter net loss
- The company reported a $782 million net loss, or $1.97 per share, versus an $825 million loss, or $2.13 per share, a year earlier.
- Cash and investments
- Moderna held $6.9 billion as of June 30, down from $7.5 billion at the end of March.
- 2026 cash outlook
- The company expects year-end cash of $4.7 billion to $5.2 billion.